在接受慢性间歇levosimendan输液的晚期心力衰竭患者中使用vericiguat:一项前性试点研究
Edoardo Sciatti1, Luca Di Odoardo1, Ottavio Zucchetti1
1Cardiovascular Department, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
Heart (British Cardiac Society)
|July 14, 2025
概括
韦里西瓜特对接受levosimendan治疗的高级心力衰竭 (AdHF) 患者有希望,改善了结果,但需要对低血压进行仔细监测. 对这一高风险群体需要进一步的研究.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 晚期心力衰竭 (AdHF) 存在重大挑战,治疗选择有限.
- 韦里西瓜特是一种新型治疗心力衰竭的治疗方法,减少排气分数 (HFrEF),在临床试验中显示出有前途.
- 在接受慢性levosimendan输液的AdHF患者中, vericiguat的安全性和有效性尚未得到充分确立.
研究的目的:
- 为了评估慢性levosimendan输液中高级心力衰竭患者的 vericiguat 的安全性和耐受性.
- 评估 vericiguat对心声回声学发现,生活质量和死亡率的影响.
主要方法:
- 一项前性研究,涉及18名晚期心力衰竭患者,每月接受levosimendan输液.
- 八名患者有资格接受输血治疗.
- 评估安全性,耐受性,心声回声学参数,生活质量和死亡率.
主要成果:
- 韦瑞西瓜特与改善心声回声检测结果,改善生活质量和降低符合条件的患者1年死亡率有关.
- 37.5%的患者因症状性低血压而停止了输血.
- 韦里西瓜特一般耐受性很好,没有发现严重的不良反应.
结论:
- 这项研究提供了第一个前性证据,证明了在慢性心力衰竭患者中安全使用 vericiguat.
- 密切监测低血压至关重要,在这个人群中药物定位可能具有挑战性.
- 需要进一步的研究,以优化这些高风险患者的治疗策略.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
733
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
733
01:22Heart Failure Drugs: Diuretics
496
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
496
01:22Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435
01:22Heart Failure VI: Adjunct Therapies
31
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
31
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
513
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
513
01:30Heart Failure V: Medical Management
27
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
27